Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
03/2004
03/02/2004CA2189007C Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
02/2004
02/26/2004WO2004016784A1 Protease inhibitor
02/26/2004WO2004016615A1 PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY
02/26/2004WO2004016611A1 Use of and some novel imidazopyridines
02/26/2004WO2004016610A1 Substituted pyrrolopyridines
02/26/2004WO2004016609A1 Substituted pyrrolopyridines
02/26/2004WO2004016608A1 Novel quinuclidine derivatives and their use
02/26/2004WO2004016606A1 Pyrazole inhibitors of the transforming growth factor
02/26/2004WO2004016601A1 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
02/26/2004WO2004016600A1 Novel use of benzothiazole derivatives
02/26/2004WO2004016590A1 The salts of the quinuclidine derivatives and the preparation and applications thereof
02/26/2004WO2004016578A2 Arylethanolamine beta2-adrenoreceptor agonist compounds
02/26/2004WO2004016270A1 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES
02/26/2004WO2004000237A3 Enhancing treatment of mdr cancer with adenosine a3 antagonists
02/26/2004WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands
02/26/2004WO2003088970A3 Modulators of hedgehog signaling pathways, compositions and uses related thereto
02/26/2004WO2003074008A3 Aminoalkylphosphonates and related compounds as edg receptor agonists
02/26/2004WO2003070155A3 Orally administrable pharmaceutical formulation
02/26/2004WO2003064443A3 New corticosteroids
02/26/2004WO2003057822A3 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
02/26/2004WO2003038058A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
02/26/2004WO2003034991A3 Taste masking spill-resistant formulation
02/26/2004WO2003026614A9 Dosage form containing a confectionery composition
02/26/2004WO2003013493A8 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
02/26/2004WO2003011899A3 Antigenic polypeptides
02/26/2004WO2003006425A9 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
02/26/2004WO2002098869A3 1,4-disubstituted benzo-fused cycloalkyl urea compounds
02/26/2004WO2002072636A8 Crystals of whole antibodies and fragments thereof and methods for making and using them
02/26/2004WO2002055075A9 Compounds and methods for regulating cell differentiation
02/26/2004WO2002055067A3 Fumaric acid derivatives as nf-kappab inhibitors
02/26/2004WO2002041885A3 Treatment of inflammation and associated complications using pseudohalides
02/26/2004WO2002022112A3 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
02/26/2004US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides
02/26/2004US20040039200 1,2,3,4,10,10a-hexahydropyrazino(1,2-a)indole derivatives useful for treating disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, and diabetes
02/26/2004US20040039198 Administering to a mammal an aromatic and heteroacromatic substituted imidazole compound to treat diseases: renal disease, wound healing, ucler, ocular disorder, diabetic nephropathy, atherosclerosis, fibrosis, ALzheimer's disease
02/26/2004US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1
02/26/2004US20040039058 Identifying a mammal having elevated concentrations of tumor necrosis factor- alpha and administering stearidonic acid (18:4, n-3) over a time period
02/26/2004US20040039049 Stable amorphous calcium pseudomonate and processes for the preparation thereof
02/26/2004US20040039038 Biaromatic compound activators of PPARy-type receptors
02/26/2004US20040039021 Pharmaceutical anti-inflammatory aerosol formulation
02/26/2004US20040039020 Novel pharmaceutical formulation suitable for nebulisation
02/26/2004US20040039017 Heterocyclic amines such as 2-(3-(4-Chloro-3-trifluoromethyl-benzylamino)prop-1-ylamino)-1H-quinolin-4 -one, used as G-protein coupled receptor inhibitors, for prophylaxis of cardiovascular disorders, schizophrenia or diabetes
02/26/2004US20040039011 Administering anticholinergic or bronchodilator agents such as tiotropium bromide for prophylaxis of respiratory system disorders
02/26/2004US20040039007 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists
02/26/2004US20040039004 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders
02/26/2004US20040038991 Imidazolyl-cyclic acetals
02/26/2004US20040038989 (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, useful as intermediates for the preparation of levodropropizine
02/26/2004US20040038979 Novel 6-heteroarylphenanthridines
02/26/2004US20040038978 Chemical compounds
02/26/2004US20040038974 Antiarthritic agents
02/26/2004US20040038969 Substituted aminopyrimidines and aminopyridazines; analgesics particularly for migraines, neuropathic pain and associated hyperalgesia and allodynia; antiinflammatory agents; treating asthma, gastrointestinal disorders, etc.
02/26/2004US20040038953 Medical combination comprising salmeterol and budesonide
02/26/2004US20040038951 Organic compounds
02/26/2004US20040038943 Indole and benzimidazole 15-lipoxygenase inhibitors
02/26/2004US20040038941 Compounds for the treatment of inflammatory disorders
02/26/2004US20040038913 Remedies for lung cancer
02/26/2004US20040038889 Fumaric acid amides
02/26/2004US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure
02/26/2004US20040038869 Inhibitors of complement activation, their preparation and use
02/26/2004US20040038370 Claudin polypeptides
02/26/2004US20040038293 Antibodies to human cd154
02/26/2004US20040038292 Comprises nucleotide sequences which code wound healing proteins for treatment and prevention of scarring, fibrosis, restenosis post angioplasty, psoriasis, benign prostatic hyperplasia, glaucoma and nervous suystem disorders
02/26/2004US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets
02/26/2004US20040038235 A g-protein coupled receptor
02/26/2004US20040038230 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
02/26/2004US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders
02/26/2004US20040038203 Comprises nucleotide sequences coding yaba monkey tumor viral protein for treatment and prevention of autoimmune diseases
02/26/2004US20040037854 Oral vaccines to prevent candida infection
02/26/2004US20040037827 Administering antibody to integrin
02/26/2004US20040037785 Method of making particles for use in a pharmaceutical composition
02/26/2004US20040037784 Particulate (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy) acetyl)amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof and one or more suitable excipients for
02/26/2004US20040037783 Pharmaceutical formulation of fluticasone propionate
02/26/2004DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects
02/26/2004DE10237739A1 Inhalable medicament for treating inflammatory or obstructive respiratory diseases, containing synergistic combination of tropane derivative anticholinergic agent, corticosteroid and beta-mimetic agent
02/26/2004CA2495511A1 Use of and some novel imidazopyridines
02/26/2004CA2495492A1 Novel use of benzothiazole derivatives
02/26/2004CA2493245A1 Novel quinuclidine derivatives and their use
02/25/2004EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
02/25/2004EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors
02/25/2004EP1391456A1 2-iminoimidazole derivative (2)
02/25/2004EP1391451A1 2-iminopyrrolidine derivates
02/25/2004EP1391202A1 Liquid drug preparations
02/25/2004EP1391201A1 Medicinal compositions
02/25/2004EP1391200A1 Drug preparations
02/25/2004EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient
02/25/2004EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor
02/25/2004EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene
02/25/2004EP1390400A2 Pharmaceutical use for secreted bacterial effector proteins
02/25/2004EP1390378A1 Pharmaceutically active uridine esters
02/25/2004EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
02/25/2004EP1390361A2 Melanocortin receptor ligands
02/25/2004EP1390357A2 Anti-thrombotic compounds, production and use thereof as medicaments
02/25/2004EP1390353A1 Triazole-derived kinase inhibitors and uses thereof
02/25/2004EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
02/25/2004EP1390348A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
02/25/2004EP1390077A2 Treatment and diagnosis of macrophage mediated disease
02/25/2004EP1390071A2 Symbiotic regenerative agent
02/25/2004EP1390067A1 Compositions for use in treating ige-associated disorders
02/25/2004EP1390062A2 Modulators of elastase inhibitor secretion
02/25/2004EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use